Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25682477 | 0.83 | LMNA (0.40) | LMNACYP2C9MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16456456 | 0.77 | MAPT (0.31) | MAPT | |
| SCHEMBL7944148 | 0.74 | — | — | |
| SCHEMBL25681878 | 0.69 | CHRM2 (0.38) | — | |
| SCHEMBL16190113 | 0.69 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21140974 | 0.69 | SMN1; SMN2 (0.41) | MAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL23315663 | 0.67 | — | — | |
| SCHEMBL18069713 | 0.67 | — | — | |
| SCHEMBL2736039 | 0.67 | — | — | |
| SCHEMBL21482965 | 0.67 | MAPT (0.34) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| WO-2021057963-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | JAK1, JAK3, JAK2 | LMNA 4581/4885CYP2C9 1707/4885MAPT 3232/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3803/4885CYP2C9 3961/4885MAPT 3364/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3803/4885CYP2C9 3961/4885MAPT 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.